Seoul/anti-pd-1-antibody-therapies-of-camrelizumab-in-combination-with-pemetrexed-and-carboplatin-as-first-line-treatment-in-patients-with-advanced-or-metastatic-non-squamous-non-small-cell-lung-cancer, South Korea